Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Pediatric Dermatology, 2024. Verfasst von July Iriani Rahardja. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
A 9-year-old boy presented with complaints of ivory and dark brown plaques on his right abdomen and right thigh [Figure 1] of 11-months duration. It had gradually progressed, hardened, and resulted in painful and restricted movement. There was no history of Raynaud’s phenomenon, dysphagia, myalgia, headache, or seizures.Figure 1: Clinical manifestation of the patient. Ivory plaques on the right bdomen (a), dark brown plaques on the right thigh (b)Questions Q1: What is your most likely diagnosis? (A). Systemic sclerosis (B): Eosinophilic fasciitis (C): Morphea (D): Linear LE panniculitis (E): Psoriasis vulgaris Q2: What clinical scores will you use for disease monitoring? (A). Modified Rodnan scores (B): The Localized Scleroderma Assessment Tool (C): Cutaneous LE Disease Area and Severity Index (D): Systemic LE Disease Activity Index (E): Psoriasis Area and Severity Index Q3: How will you treat the patient if there is physical deformity (joint contractures) and functional impairment? (A). Topical corticosteroid (B): Topical calcipotriol (C): Systemic methotrexate (D): Surgery (E): PUVA Discussion Morphea, also known as localized scleroderma, is a rare, fibrosing skin disorder caused by excessive collagen production resulting in thickening of the skin, down to subcutaneous fat. It can also affect underlying bone and muscle and can occasionally involve the central nervous system.[1,2] It is characterized by inflammatory patches and/or bands of thickened skin on the head and neck area, trunk, and limbs. Morphea is differentiated from systemic sclerosis (scleroderma) based on the absence of sclerodactyly, Raynaud’s phenomenon, internal organ involvement, and nail-fold capillary changes.[1-4] Monitoring the severity and activity of morphea poses a significant difficulty. Clinical scores like the modified Rodnan score, which is validated for systemic sclerosis, have limited utility in tracking morphea progression. The Localized Scleroderma Cutaneous Assessment Tool is currently being assessed and encompasses evaluations of both disease activity and skin damage.[4] Systemic therapy with agents, such as methotrexate, mycophenolate mofetil, D-penicillamine, and cyclosporine, may be considered in children with progressive or extensive cutaneous disease with lesions affecting the face or overlying joints to prevent complications such as functional impairment and joint contractures. Phototherapy, including psoralen plus ultraviolet A or narrowband ultraviolet B light, may be considered in patients with morphea without risk of joint contractures.[3,4] Answers Q1: What is your most likely diagnosis? Morphea Q2: What clinical scores will you use for disease monitoring? (B). The Localized Scleroderma Assessment Tool Q3: How will you treat the patient if there is physical deformity (joint contractures) and functional impairment? (C): Systemic methotrexate Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Zitieren
APA
Rahardja, J. I. (2024). Morphea. Asian Journal of Pediatric Dermatology. https://doi.org/10.4103/ajpd.ajpd_10_24
Vancouver
Rahardja JI. Morphea. Asian Journal of Pediatric Dermatology. 2024. doi:10.4103/ajpd.ajpd_10_24
BibTeX
@article{Rahardja2024,
author = {Rahardja, July Iriani},
title = {Morphea},
journal = {Asian Journal of Pediatric Dermatology},
year = {2024},
doi = {10.4103/ajpd.ajpd_10_24}
}
EUVIMED